Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

American Heart Journal
J TsevatL Goldman

Abstract

The objective of this study was to assess the cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels. We performed a cost-effectiveness analysis based on actual clinical, cost, and health-related quality-of-life data from the Cholesterol and Recurrent Events (CARE) trial. Survival and recurrent coronary heart disease events were modeled from trial data in Markov models, with the use of different assumptions regarding the long-term benefit of therapy. Pravastatin therapy increased quality-adjusted life expectancy at an incremental cost of $16,000 to $32,000 per quality-adjusted life-year gained. In subgroup analyses, the cost-effectiveness of pravastatin therapy was more favorable for patients >60 years of age and for patients with pretreatment low-density lipoprotein cholesterol levels >125 mg/dL. Results were sensitive to the cost of pravastatin and to assumptions about long-term survival benefits from pravastatin therapy. The cost-effectiveness of pravastatin therapy in survivors of myocardial infarction with average cholesterol levels compares favorably with other interventions.

References

Mar 1, 1980·Clinical Obstetrics and Gynecology·L Weinstein
Jan 1, 1982·Annals of Internal Medicine·S A Finkler
Oct 1, 1995·Journal of the American College of Cardiology·J TsevatT H Lee
Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
May 15, 1996·Annals of Internal Medicine·J M GazianoC H Hennekens
Aug 15, 1996·The American Journal of Cardiology·T AshrafL Radican
Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Feb 19, 1997·JAMA : the Journal of the American Medical Association·M G HuninkM C Weinstein
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group

❮ Previous
Next ❯

Citations

Sep 19, 2008·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Douglas C A TaylorMilton C Weinstein
Dec 8, 2007·European Journal of Epidemiology·Wolfgang C WinkelmayerUNKNOWN Pharmacoeconomics Advisory Council of the Austrian Sickness Funds
Jun 7, 2002·The New England Journal of Medicine·Jean-Michel GaspozLee Goldman
Oct 20, 2005·Journal of Epidemiology and Community Health·Oscar H FrancoLuc Bonneux
Sep 16, 2006·Journal of Epidemiology and Community Health·Oscar H FrancoLuc Bonneux
Jan 1, 2010·Ecancermedicalscience·P KanavosZ Vlachopioti
Oct 13, 2009·Expert Review of Pharmacoeconomics & Outcomes Research·Roberta AraAbdullah Pandor
Apr 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Robert C Kaplan, Clyde Schechter
Nov 3, 2010·Journal of Evaluation in Clinical Practice·Siok Swan TanLeona Hakkaart-van Roijen
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Katie M Speidel, Daniel E Hilleman
Oct 11, 2011·Journal of the American College of Cardiology·Bob J H van KempenM G Myriam Hunink
Jul 10, 2002·Journal of the American College of Cardiology·Gavin J BlakeKaren M Kuntz
May 13, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Bryan R LuceL Clark Paramore
Sep 12, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Spencer B CherryMichael B Nichol
Nov 17, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Chris KnightJeno P Marton
Jun 22, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John RecklessPhilippe Brudi
Jun 2, 2012·The American Journal of Cardiology·Soyon LeeCraig I Coleman
Jul 28, 2016·BMC Public Health·Shari P FeirmanAndrea C Villanti
Dec 26, 2006·Health Care Management Science·K CooperJ Raftery
Jun 14, 2005·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Afschin Gandjour, Karl Wilhelm Lauterbach
Jun 6, 2006·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Wolfgang C WinkelmayerJerry Avorn
May 23, 2008·Journal of Cardiovascular Pharmacology and Therapeutics·William S Weintraub
May 3, 2011·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Jennifer E MasonNilay D Shah
Nov 18, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Dong-Churl SuhTaehwan Park
Dec 16, 2006·Clinical Trials : Journal of the Society for Clinical Trials·Mark A HlatkyGillian D Sanders
Mar 6, 2007·PharmacoEconomics·Pearl D GumbsOlaf H Klungel
Feb 4, 2003·Current Atherosclerosis Reports·Dean G Smith

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine
Jonas B ThorlundEva Ageberg
© 2021 Meta ULC. All rights reserved